As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it thinks ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

The agreement resolves the patent litigation brought by Amicus in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Galafold (migalastat ...

Austedo, Teva's treatment for tardive dyskinesia and chorea associated with Huntington's disease, has been a standout performer with projected year-over-year growth of 20%. The generic drug ...

Teva recorded double-digit sales growth in generic drugs as well as in sales of its trio of key branded medicines. "2025 will be a bit of more of the same - more innovative growth, the ability to ...

BRUSSELS (AP) — The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its ...